secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001193125-24-131920
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus Pharmaceuticals raises $30.2M in registered direct offering with CEO participation
--------------------------------------------------------------------------------

- Entered Securities Purchase Agreement on May 1, 2024 to issue ~13.5M shares and warrants at $1.7312 per combined unit
- Net proceeds expected ~$30.2M; closing expected May 6, 2024
- Common warrants exercisable at $3.50/share, expiring June 30, 2025
- CEO and existing institutional investors participated in the offering
- Proceeds to be used for working capital, R&D, and general corporate purposes

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000119312524131920/0001193125-24-131920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000119312524131920/d790042d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-131920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer